Showing 2111-2120 of 3039 results for "".
- Retina Consultants of America Continues Growth by Adding Pacific Northwest Retinahttps://modernod.com/news/retina-consultants-of-america-continues-growth-by-adding-pacific-northwest-retina/2480461/Retina Consultants of America (RCA), a
- Allergan to Present Data from its Eye Care Portfolio at the AAO Annual Meeting, Including New Vuity Analysishttps://modernod.com/news/allergan-to-present-data-from-its-eye-care-portfolio-at-the-aao-annual-meeting-including-new-vuity-analysis/2480415/
- EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s Sharpened Clinical Development Strategyhttps://modernod.com/news/eyegate-is-now-kiora-pharmaceuticals-provides-update-on-companys-sharpened-clinical-development-strategy/2480411/Kiora Pharmaceuticals is the new name of EyeGate Pharmaceuticals. The new brand reflects the company’s aim to not only treat common eye conditions, but to develop a small molecule therapy for retinitis pigmentosa. Kiora will trade on the Nasdaq
- FDA Approves Genentech’s Port Delivery System, Susvimo, a First-of-Its-Kind Therapeutic Approach for Wet AMDhttps://modernod.com/news/fda-approves-genentechs-port-delivery-system-susvimo-a-first-of-its-kind-therapeutic-approach-for-wet-amd/2480373/Genentech announced that the FDA has approved Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with wet age-related macular degeneration (AMD) who have previously responded to at least two anti-vascular endothelial growth fact
- MeiraGTx Announces the Presentation of Two Novel Inherited Retinal Disease (IRD) Programs and Riboswitch Gene Regulation Platformhttps://modernod.com/news/meiragtx-announces-the-presentation-of-two-novel-inherited-retinal-disease-ird-programs-and-riboswitch-gene-regulation-platform/2480359/MeiraGTx announced three poster presentations at the European Society of Gene and Cell Therapy (ESGCT) 2021 Annual Congress. Two preclinical programs addressing inherited retinal diseases (IRDs) caused by mutations in KCNV2 and GUCY2D are presented with
- Atsena Therapeutics Unveils XLRS Gene Therapy Program Leveraging Novel Spreading Capsidshttps://modernod.com/news/atsena-therapeutics-unveils-xlrs-gene-therapy-program-leveraging-novel-spreading-capsids/2480355/Atsena Therapeutics unveiled its preclinical gene therapy program for X-linked retinoschisis (XLRS), a monogenic disease caused by mutations in the RS1 gene. XLRS is characterized by schisis, or abnormal splitting of the layers of the retina, which causes impa
- Ocuphire Announces Publications Featuring the Ref-1 Protein as a Novel Therapeutic Target for the Treatment of Neovascular Retinal Diseaseshttps://modernod.com/news/ocuphire-announces-publications-featuring-the-ref-1-protein-as-a-novel-therapeutic-target-for-the-treatment-of-neovascular-retinal-diseases/2480333/
- Bausch + Lomb Announces Statistically Significant Topline Results from Second Phase 3 Trial of NOV03 for Dry Eye Diseasehttps://modernod.com/news/bausch-lomb-announces-statistically-significant-topline-results-from-second-phase-3-trial-of-nov03-for-dry-eye-disease/2480310/
- US Eye Adds New Partnerships in Virginia, North Carolina, South Carolina, and Floridahttps://modernod.com/news/us-eye-adds-new-partnerships-in-virginia-north-carolina-south-carolina-and-florida/2480301/The US Eye practice network has recently expanded its practice base to 50 clinics and five surgery centers across the southeastern United States. Financial terms of the deal were not disclosed. US Eye has partnered with Griffey Eye Care located in Chesapeake, Virginia; Al
- Visus Therapeutics Expands Ophthalmic Drug Portfolio With Investigational Therapies for Glaucoma and AMDhttps://modernod.com/news/visus-therapeutics-expands-ophthalmic-drug-portfolio-with-investigational-therapies-for-glaucoma-and-amd/2479457/Visus Therapeutics announced it has entered into a worldwide exclusive licensing agreement with Cella Therapeutics to develop an array of investigational ophthalmic therapies to treat glaucoma and age-related macular degeneration (AMD). The company also announced a worldwide exclusive licensing a